| Paroxysmal nocturnal hemoglobinuria
PiaSky vs Voydeya
Side-by-side clinical, coverage, and cost comparison for paroxysmal nocturnal hemoglobinuria.Deep comparison between: Piasky vs Voydeya with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVoydeya has a higher rate of injection site reactions vs Piasky based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Voydeya but not Piasky, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Piasky
Voydeya
At A Glance
IV infusion / SC injection
Every 4 weeks (maintenance)
Complement C5 inhibitor
Oral
Three times daily
Complement Factor D inhibitor
Indications
- Paroxysmal nocturnal hemoglobinuria
- Paroxysmal nocturnal hemoglobinuria
Dosing
Paroxysmal nocturnal hemoglobinuria Loading: 1,000 mg (>=40 kg to <100 kg) or 1,500 mg (>=100 kg) IV on Day 1, then 340 mg SUBQ on Days 2, 8, 15, and 22; maintenance 680 mg (>=40 kg to <100 kg) or 1,020 mg (>=100 kg) SUBQ every 4 weeks starting Day 29.
Paroxysmal nocturnal hemoglobinuria 150 mg orally three times a day as starting dose; may increase to 200 mg three times a day if hemoglobin has not increased by >2 g/dL after 4 weeks, if transfusion was required in the previous 4 weeks, or based on clinical judgment.
Contraindications
- Unresolved serious Neisseria meningitidis infection
- Known serious hypersensitivity reaction to crovalimab or any excipient
- Unresolved serious infection caused by encapsulated bacteria, including Neisseria meningitidis, Streptococcus pneumoniae, or Haemophilus influenzae type B
Adverse Reactions
Most common (>=10%) Infusion-related reaction, respiratory tract infection, viral infection, Type III hypersensitivity reaction, peripheral edema, headache
Serious Epistaxis, pneumonia, infusion-related reaction, pyelonephritis, COVID-19, hypovolemic shock, nasopharyngitis, urinary tract infection
Most common (>=10%) Headache
Serious Pancreatitis, cholecystitis, blood bilirubin increased
Pharmacology
Crovalimab-akkz is a humanized IgG1 monoclonal antibody that binds with high affinity to complement protein C5, inhibiting its cleavage into C5a and C5b and preventing formation of the membrane attack complex (MAC), thereby inhibiting terminal complement-mediated intravascular hemolysis in patients with PNH.
Complement Factor D inhibitor; danicopan binds reversibly to Factor D and selectively inhibits the alternative complement pathway, preventing C3 convertase formation, reducing C3 fragment opsonization, and thereby controlling extravascular hemolysis in PNH when used as add-on therapy to a terminal complement inhibitor.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Piasky
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
Voydeya
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Piasky
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Voydeya
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (3/8)
Humana
Piasky
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Voydeya
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0
Alexion OneSourceCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
PiaskyView full Piasky profile
VoydeyaView full Voydeya profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.